Non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta‐analysis of randomized trials

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 11, 2015-11 ,pp. : 1192-1200

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 1, 2018-01 ,pp. : 6-18

John Wiley & Sons Inc

Access to resources Recommend Favorite

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

By Heidbuchel Hein   Verhamme Peter   Alings Marco   Antz Matthias   Hacke Werner   Oldgren Jonas   Sinnaeve Peter   Camm A. John   Kirchhof Paulus  

EP-Europace, Vol. 15, Iss. 5, 2013-05 ,pp. : 625-651

Oxford University Press

Access to resources Recommend Favorite

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 11, 2015-11 ,pp. : 2119-2126

John Wiley & Sons Inc

Access to resources Recommend Favorite

An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation

By Leigh J. Paul   White Richard H.  

Current Medical Research and Opinion, Vol. 23, Iss. 9, 2007-09 ,pp. : 2071-2081

Informa Healthcare

Access to resources Recommend Favorite